Unlocking the Potential – A Guide to Bio-Techne Corp

By Scott Lee • Tuesday, September 02 15:26 • Permanent Link

Bio-Techne Corp logged a -2.8% change during today's afternoon session, and is now trading at a price of $53.12 per share. The S&P 500 index moved -1.0%. TECH's trading volume is 1,092,859 compared to the stock's average volume of 2,147,196.

Bio-Techne Corp trades -18.66% away from its average analyst target price of $65.31 per share. The 13 analysts following the stock have set target prices ranging from $53.0 to $75.0, and on average have given Bio-Techne Corp a rating of buy.

Anyone interested in buying TECH should be aware of the facts below:

Bio-Techne Corp's current price is 203.9% above its Graham number of $17.48, which implies that at its current valuation it does not offer a margin of safety
Bio-Techne Corp has moved -23.8% over the last year, and the S&P 500 logged a change of 16.8%
Based on its trailing earnings per share of 0.46, Bio-Techne Corp has a trailing 12 month Price to Earnings (P/E) ratio of 115.5 while the S&P 500 average is 29.3
TECH has a forward P/E ratio of 24.3 based on its forward 12 month price to earnings (EPS) of $2.19 per share
Its Price to Book (P/B) ratio is 4.29 compared to its sector average of 3.19
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Based in Minneapolis, the company has 3,100 full time employees and a market cap of $8.26 Billion. Bio-Techne Corp currently returns an annual dividend yield of 0.6%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.